Editas Surpasses Therapeutic Gene Editing Threshold in New Preclinical Data
| EDIT Stock | USD 2.60 0.04 1.56% |
Slightly above 55% of Editas Medicine's private investors are presently thinking to get in. The analysis of overall sentiment of trading Editas Medicine stock suggests that some investors are interested at this time. Editas Medicine's investing sentiment can be driven by a variety of factors including economic data, Editas Medicine's earnings reports, geopolitical events, and overall market trends.
Editas Medicine, Inc. ranks among the best CRISPR stocks to buy. At the European Hematology Association 2025 Congress on June 12, Editas Medicine, Inc. revealed new in vivo data showing notable progress in gene editing for beta thalassemia and sickle cell disease. According to the study, a single dose of the companys proprietary
Read at finance.yahoo.com
 |
Editas Medicine Fundamental Analysis
We analyze Editas Medicine's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Editas Medicine using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Editas Medicine based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Asset
Current Asset Comparative Analysis
Editas Medicine is currently under evaluation in current asset category among its peers. Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Editas Medicine Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Editas Medicine stock to make a market-neutral strategy. Peer analysis of Editas Medicine could also be used in its relative valuation, which is a method of valuing Editas Medicine by comparing valuation metrics with similar companies.
Peers
Editas Medicine Related Equities
| NTLA | Intellia Therapeutics | 5.48 | ||||
| DNA | Ginkgo Bioworks | 5.00 | ||||
| ALLO | Allogene Therapeutics | 1.85 | ||||
| SANA | Sana Biotechnology | 0.71 | ||||
| BEAM | Beam Therapeutics | 2.20 | ||||
| CRBU | Caribou Biosciences | 2.86 | ||||
| PRME | Prime Medicine, | 2.89 | ||||
| CRSP | Crispr Therapeutics | 6.71 | ||||
| VRTX | Vertex Pharmaceuticals | 20.60 |
Additional Tools for Editas Stock Analysis
When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.